http://jnci.oxfordjournals.org/content/98/10/708.full
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/98/10/708" />
      <meta content="/jnci/98/10/708.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients"
            name="DC.Title" />
      <meta content="10.1093/jnci/djj189" name="DC.Identifier" />
      <meta content="2006-05-17" name="DC.Date" />
      <meta content="Oxford University Press" name="DC.Publisher" />
      <meta content="Julia Bohlius" name="DC.Contributor" />
      <meta content="Jayne Wilson" name="DC.Contributor" />
      <meta content="Jerome Seidenfeld" name="DC.Contributor" />
      <meta content="Margaret Piper" name="DC.Contributor" />
      <meta content="Guido Schwarzer" name="DC.Contributor" />
      <meta content="Josie Sandercock" name="DC.Contributor" />
      <meta content="Sven Trelle" name="DC.Contributor" />
      <meta content="Olaf Weingart" name="DC.Contributor" />
      <meta content="Sue Bayliss" name="DC.Contributor" />
      <meta content="Benjamin Djulbegovic" name="DC.Contributor" />
      <meta content="Charles L. Bennett" name="DC.Contributor" />
      <meta content="Simon Langensiepen" name="DC.Contributor" />
      <meta content="Chris Hyde" name="DC.Contributor" />
      <meta content="Andreas Engert" name="DC.Contributor" />
      <meta content="Journal of the National Cancer Institute"
            name="citation_journal_title" />
      <meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
      <meta content="0027-8874" name="citation_issn" />
      <meta content="1460-2105" name="citation_issn" />
      <meta name="citation_author" content="Julia Bohlius" />
      <meta name="citation_author" content="Jayne Wilson" />
      <meta name="citation_author" content="Jerome Seidenfeld" />
      <meta name="citation_author" content="Margaret Piper" />
      <meta name="citation_author" content="Guido Schwarzer" />
      <meta name="citation_author" content="Josie Sandercock" />
      <meta name="citation_author" content="Sven Trelle" />
      <meta name="citation_author" content="Olaf Weingart" />
      <meta name="citation_author" content="Sue Bayliss" />
      <meta name="citation_author" content="Benjamin Djulbegovic" />
      <meta name="citation_author" content="Charles L. Bennett" />
      <meta name="citation_author" content="Simon Langensiepen" />
      <meta name="citation_author" content="Chris Hyde" />
      <meta name="citation_author" content="Andreas Engert" />
      <meta content="Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients"
            name="citation_title" />
      <meta content="05/17/2006" name="citation_date" />
      <meta content="98" name="citation_volume" />
      <meta content="10" name="citation_issue" />
      <meta content="708" name="citation_firstpage" />
      <meta content="714" name="citation_lastpage" />
      <meta content="98/10/708" name="citation_id" />
      <meta content="98/10/708" name="citation_id_from_sass_path" />
      <meta content="jnci;98/10/708" name="citation_mjid" />
      <meta content="10.1093/jnci/djj189" name="citation_doi" />
      <meta content="http://jnci.oxfordjournals.org/content/98/10/708.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/98/10/708.full"
            name="citation_fulltext_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/98/10/708.full.pdf"
            name="citation_pdf_url" />
      <meta content="http://jnci.oxfordjournals.org/content/98/10/708"
            name="citation_public_url" />
      <meta content="16705125" name="citation_pmid" />
      <meta name="citation_section" content="Brief Communication" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/98/10/700.short" rel="prev" />
      <link href="/content/98/10/715.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-local-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-ac.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d28899850e1">var callbackToken='537BCE63E5B89D3';</script><script type="text/javascript" id="session-d28899850e3">
                      var subCode='oupjournal_sub';
                    </script><script type="text/javascript">
            var gAuthTimeStamp = '2015-10-27T12:12:55.897-07:00';
            var gSessionId = 'n0E8h5OcUaSB7yu9V3JVTQ';
            var gAuthzRequired = 'false';
            var gAuthnMethods1 = 'ip ip';
            var gAuthnMethods2 = 'ip,ip';
            var gAuthnIPs = '18.189.59.169,18.189.59.169';
            var gAuthnIndividuals = '';
            var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
            </script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
              src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
          MathJax.Hub.Queue(function() {
            gColTempResize = true;
            fixColHeights(1);
            gColTempResize = false;
          });
       </script><script type="text/javascript"
              src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
	    
	    
	    
	    var siqDOI = encodeURIComponent("10.1093/jnci/djj189");
	    var siqIsOpenAccess = encodeURIComponent("");
	    var siqPubDate = encodeURIComponent("17 May 2006");

	    if (siqDOI.length == 0) {
	        siqDOI = "UNKNOWN";
	    }
	    
	    
		
		
	    if (gAuthnIndividuals.length != 0) {
		if (gAuthnInstitutions.length != 0) {
		    authnEntity = encodeURIComponent(gAuthnIndividuals
		        + ',' + gAuthnInstitutions);
		} else {
		    authnEntity = encodeURIComponent(gAuthnIndividuals);
		}
	    } else {
	        authnEntity = encodeURIComponent(gAuthnInstitutions);
	    }

	    var commonString =
		'authSessionId=' + gSessionId + String.fromCharCode(0x26)
		+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
		+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
		+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
		+ 'authnInstitutions=' + authnEntity;

		
		
		
		

	    var gPageId = "pageid-content";
	    var gVariant = "full-text";

	    
		// Not completely done
		var eventType = "full-text";
		var accessType;
		if (siqIsOpenAccess == 'true') {
		    accessType = 'SOA';
		} else {
		    accessType = 'subscription';
		}
		    
		var NTPT_PGEXTRA =
		    commonString + String.fromCharCode(0x26)
		    + 'event_type=' + eventType + String.fromCharCode(0x26)
		    + 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
		    + 'access_type=' + accessType + String.fromCharCode(0x26)
		    + 'doi=' + siqDOI ;
		    
		

	    // alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
	</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-header.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-footer.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-sidebars.css" />
      <link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
      <link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
            href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
      <link rel="stylesheet" type="text/css" media="screen"
            href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
   <body class="general_page journal jnci">
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
           itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <noscript>
            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
                     JNCI J Natl Cancer Inst
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jnci/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution:  MIT Libraries</li>
                     <li class="no-left-border">
                        <a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F98%2F10%2F708.full">
                           Sign In as Personal Subscriber
                           </a>
                        
                     </li>
                  </ul>           
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
                     class="breadcrumb_subject">Medicine &amp; Health</a></span></li>
            <li><a href="/">JNCI J Natl Cancer Inst</a></li>
            <li><a href="/content/98/10.toc">
                  <span xmlns="" class="volume-value">Volume 98</span>
                  <span xmlns="" class="issue-value"> Issue 10</span></a></li>
            <li>Pp. <span class="slug-pages">
                  708-714.
                  </span></li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top"
                    src="/resource/htmlfiles/advert.html?p=Top&amp;u=jnci.oxfordjournals.org/content/98/10/708.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div id="content-block">
            <div class="article fulltext-view" itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients</h1>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Julia+Bohlius&amp;sortspec=date&amp;submit=Submit">Julia Bohlius</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Jayne+Wilson&amp;sortspec=date&amp;submit=Submit">Jayne Wilson</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-3" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Jerome+Seidenfeld&amp;sortspec=date&amp;submit=Submit">Jerome Seidenfeld</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-4" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Margaret+Piper&amp;sortspec=date&amp;submit=Submit">Margaret Piper</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-5" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Guido+Schwarzer&amp;sortspec=date&amp;submit=Submit">Guido Schwarzer</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-6" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Josie+Sandercock&amp;sortspec=date&amp;submit=Submit">Josie Sandercock</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-7" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Sven+Trelle&amp;sortspec=date&amp;submit=Submit">Sven Trelle</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-8" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Olaf+Weingart&amp;sortspec=date&amp;submit=Submit">Olaf Weingart</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-9" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Sue+Bayliss&amp;sortspec=date&amp;submit=Submit">Sue Bayliss</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-10" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Benjamin+Djulbegovic&amp;sortspec=date&amp;submit=Submit">Benjamin Djulbegovic</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-11" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Charles+L.+Bennett&amp;sortspec=date&amp;submit=Submit">Charles L. Bennett</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-12" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Simon+Langensiepen&amp;sortspec=date&amp;submit=Submit">Simon Langensiepen</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-13" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Chris+Hyde&amp;sortspec=date&amp;submit=Submit">Chris Hyde</a></span> and 
                     </li>
                     <li class="last" id="contrib-14"><span class="name"><a class="name-search"
                              href="/search?author1=Andreas+Engert&amp;sortspec=date&amp;submit=Submit">Andreas Engert</a></span></li>
                  </ol>
                  <ol class="affiliation-list">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address><em>Affiliations of authors:</em> Department of Internal Medicine I, University of Cologne, Germany (JB, ST, OW, SL, AE); Department of Public Health and Epidemiology,
                           University of Birmingham, U.K. (JW, J. Sandercook, SB, CH); Technology Evaluation Center, Blue Cross and Blue Shield Association,
                           Chicago, IL (J. Seidenfeld, MP); Institute of Medical Biometry and Medical Informatics, University of Freiburg, Germany (GS);
                           H. Lee Moffitt Cancer Center, Tampa, FL (BD); Department of Veterans Affairs Chicago Healthcare System, Lakeside Division
                           and Northwestern University Chicago, IL (CLB)
                        </address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="fn" id="corresp-1"><em>Correspondence to:</em> Julia Bohlius, MD, MScPH, University Hospital of Cologne Department I of Internal Medicine, 50924 Cologne, Germany (e-mail:
                        <span class="em-link"><span class="em-addr">julia.bohlius{at}uk-koeln.de</span></span>).
                     </li>
                  </ol>
                  <ul class="history-list">
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="received"
                         hwp:start="2005-12-01"><span class="received-label">Received </span>December 1, 2005.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd"
                         hwp:start="2006-03-17"><span class="rev-recd-label">Revision received </span>March 17, 2006.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted"
                         hwp:start="2006-03-21"><span class="accepted-label">Accepted </span>March 21, 2006.
                     </li>
                  </ul>
               </div>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#fn-group-1" title="Footnotes" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  
                  <p id="p-1">This is an updated systematic review of 57 trials and 9353 cancer patients from articles, abstracts, and reports published
                     between January 1, 1985, and April 30, 2005, on the effects of epoetin alfa and beta (i.e., epoetin) and darbepoetin alfa
                     (i.e., darbepoetin). We included randomized controlled trials comparing epoetin or darbepoetin plus red blood cell transfusion
                     with red blood cell transfusion alone for prophylaxis or treatment of anemia in cancer patients with or without concurrent
                     antineoplastic therapy. The Cochrane Library, MEDLINE, EMBASE, and conference proceedings were searched. Effect estimates
                     and 95% confidence intervals (CIs) were calculated with fixed-effects models. Treatment with epoetin or darbepoetin statistically
                     significantly reduced the risk for red blood cell transfusions (relative risk [RR] = 0.64, 95% CI = 0.60 to 0.68; 42 trials
                     and 6510 patients) and improved hematologic response (RR = 3.43, 95% CI = 3.07 to 3.84; 22 trials and 4307 patients). Treatment
                     with epoetin or darbepoetin increased the risk of thrombo-embolic events (RR = 1.67, 95% CI = 1.35 to 2.06; 35 trials and
                     6769 patients). Uncertainties remain as to whether and how epoetin or darbepoetin affects overall survival (hazard ratio =
                     1.08, 95% CI = 0.99 to 1.18; 42 trials and 8167 patients). Caution is advised when using epoetin or darbepoetin in combination
                     with thrombogenic chemotherapeutic agents or for cancer patients who are at high risk for thrombo-embolic events.
                  </p>
                  
               </div>
               <p id="p-2">Clinical studies and subsequent meta-analyses <em>(<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>–<a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">5</a>)</em> have found that erythropoietins increase hemoglobin levels and reduce the need for blood transfusions in cancer patients.
                  However, there is conflicting evidence concerning the association between erythropoietins and tumor control or survival <em>(<a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a>–<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a>),</em> and erythropoietins may even increase risk for thombo-embolic events <em>(<a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a>)</em>.
               </p>
               <p id="p-3">We report an updated Cochrane Review on hematologic responses, red blood cell transfusions, thrombo-embolic events, and overall
                  survival in cancer patients receiving epoetin or darbepoetin. Additional outcomes (tumor response, quality of life, hemoglobin
                  change, and other adverse events) will be reported elsewhere <em>(<a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">3</a>)</em>.
               </p>
               <p id="p-4">The literature searches covered the period from January 1, 1985, to December 31, 2001, for the first Cochrane Review <em>(<a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4</a>)</em> and also included articles from January 1, 2002, to April 30, 2005, for the update. The Cochrane Library, MEDLINE, EMBASE,
                  and conference proceedings were searched. Materials presented at a May 2004 U.S. Food and Drug Administration (FDA) hearing
                  related to overall survival and thrombo-embolic event were also reviewed <em>(<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>)</em> [for details, see <em>(<a id="xref-ref-3-2" class="xref-bibr" href="#ref-3">3</a>)</em>]. We included randomized controlled trials comparing epoetin or darbepoetin plus red blood cell transfusion with red blood
                  cell transfusion alone for prophylaxis or treatment of anemia in cancer patients with or without concurrent antineoplastic
                  therapy to prevent or reduce anemia. Control groups of included studies received identical antineoplastic and supportive treatments.
                  Ongoing and small studies (≤10 patients per study arm) were excluded. Study selection, quality assessment, and data extraction
                  were carried out independently by two reviewers. Additional unreported data were obtained from the investigators for the first
                  review but not for the update, because of time constraints. Effect measures used were relative risks (RRs) for binary data
                  and hazard ratios (HRs) for overall survival. Hazard ratios were calculated with individual patient data or with data from
                  published reports <em>(<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a>)</em>. Effect estimates and 95% confidence intervals (CIs) were calculated with fixed-effects models and pooled by use of the Mantel–Haenszel
                  method. Homogeneity tests and tests for subgroup differences were one-sided; all other tests were two-sided. The <em>P</em> value of the homogeneity test and the <em>I</em><sup>2</sup> statistic were used to assess the extent of heterogeneity across trials in each meta-analysis. Results were recalculated
                  with a random-effects model when statistically significant heterogeneity was present. Potential causes of heterogeneity were
                  explored with subgroup analyses for the following prespecified factors: hemoglobin at baseline, tumor entity, antineoplastic
                  therapy, duration of epoetin or darbepoetin treatment, methodologic quality (allocation concealment, intention-to-treat analysis,
                  double-blinding), and source of data. Exploratory subgroup analyses included epoetin versus darbepoetin, epoetin dosages (&lt;40 000
                  IU/week or ≥40 000 IU/week), administration in accordance with FDA license indication, stopping epoetin or darbepoetin (hematocrit
                  of ≤40% or &gt;40%, where a hematocrit of 40% = a hemoglobin level of 13.3 g/dL), treatment versus maintenance trials, and final
                  hemoglobin level (≤13.3 g/dL or &gt;13.3 g/dL). The current product labels recommended that the dose be reduced or administration
                  be stopped at a hemoglobin level of 13 g/dL. We identified four studies <em>(<a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a>–<a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a>,<a id="xref-ref-27-1" class="xref-bibr" href="#ref-27">27</a>)</em> that stopped drug administration when the hemoglobin level reached a maximun level of 13 g/dL. Three studies <em>(<a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a>–<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a>)</em> stopped administration of epoetin at a slightly higher level of hemoglobin (hemoglobin = 13.3 g/dL or hematocrit = 40%) than
                  the currently recommended hemoglobin level of 13 g/dL. We therefore set the cutoff at a hemoglobin level of 13.3g/dL or a
                  hematocrit level of 40%. Using either a hemoglobin level of 13.0 g/dL or 13.3 g/dL as the cutoff did not alter the results
                  substantially. Analyses were performed with the Review Manager program (RevMan version 4.2.7) and the statistical software
                  package R <em>(<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>)</em>.
               </p>
               <p id="p-5">Literature searches yielded 1592 references for the first Cochrane review and 1859 references for the update. Overall, 165
                  publications were retrieved for detailed examination, of which 108 trials were excluded, 79 for not meeting selection criteria,
                  and 29 were still ongoing (<a id="xref-fig-1-1" class="xref-fig" href="#F1">Fig. 1</a>). A total of 57 randomized controlled trials with 9353 patients were included, of which 27 studies with 3287 participants
                  were analyzed in the first review <em>(<a id="xref-ref-6-2" class="xref-bibr" href="#ref-6">6</a>,<a id="xref-ref-12-2" class="xref-bibr" href="#ref-12">12</a>–<a id="xref-ref-15-2" class="xref-bibr" href="#ref-15">15</a>,<a id="xref-ref-17-2" class="xref-bibr" href="#ref-17">17</a>,<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a>–<a id="xref-ref-39-1" class="xref-bibr" href="#ref-39">39</a>)</em> and another 30 studies with 6066 participants <em>(<a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a>,<a id="xref-ref-8-2" class="xref-bibr" href="#ref-8">8</a>,<a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">16</a>,<a id="xref-ref-40-1" class="xref-bibr" href="#ref-40">40</a>–<a id="xref-ref-66-1" class="xref-bibr" href="#ref-66">66</a>)</em> were included for the update (Supplemental Table 1, available at: <a href="http://jncicancerspectrum.oxfordjournals.org/jnci/content/vol98/issue10">http://jncicancerspectrum.oxfordjournals.org/jnci/content/vol98/issue10</a>).
                  
               </p>
               <div id="F1" class="fig pos-float odd">
                  <div class="fig-inline"><a href="708/F1.expansion.html"><img alt="Fig. 1." src="708/F1.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                           <li><a href="708/F1.expansion.html">In this window</a></li>
                           <li><a class="in-nw" href="708/F1.expansion.html">In a new window</a></li>
                        </ul>
                        <ul class="fig-services">
                           <li class="ppt-link"><a href="/powerpoint/98/10/708/F1">Download as PowerPoint Slide</a></li>
                        </ul>
                     </div>
                  </div>
                  <div class="fig-caption"><span class="fig-label"><strong>Fig. 1.</strong></span> 
                     <p id="p-6" class="first-child">QUOROM Flow diagram. The process of identifying and evaluating randomized controlled trials (RCTs) for the first review (1985
                        to December 2001) and the update (January 2002 to April 2005).
                     </p>
                     <div class="sb-div caption-clear"></div>
                  </div>
               </div>
               <p id="p-7">Meta-analysis found that patients treated with epoetin or darbepoetin had a 36% lower risk of transfusion than control subjects
                  (fixed-effects RR = 0.64, 95% CI = 0.60 to 0.68; random-effects RR = 0.62, 95% CI = 0.57 to 0.69; 42 trials and 6510 patients;
                  test for heterogeneity <em>P</em>&lt;.001 and <em>I</em><sup>2</sup> = 51.3%). In addition, patients receiving epoetin or darbepoetin were more likely to achieve hematologic response, defined
                  as a hemoglobin increase of 2 g/dL (fixed-effects RR = 3.43, 95% CI = 3.07 to 3.84; random-effects RR = 3.52, 95% CI = 2.95
                  to 4.20; 22 trials and 4307 patients; test for heterogeneity <em>P</em> = .01 and <em>I</em><sup>2</sup> = 38.5%).
               </p>
               <p id="p-8">On the basis of 6769 patients in 35 trials, thrombo-embolic events (such as transient ischemic attacks, stroke, pulmonary
                  emboli, deep vein thrombosis, and myocardial infarction) were observed in 229 of the 3728 patients treated with epoetin or
                  darbepoetin (median = 4.5%, range = 0%–30%) and in 118 of the 3041 untreated control patients (median = 1.4%, range 0%-22.6%).
                  Thus, the relative risk of a thrombo-embolic event was increased by 67% in the treated group compared with the control group
                  (RR = 1.67, 95% CI = 1.35 to 2.06) (<a id="xref-fig-2-1" class="xref-fig" href="#F2">Fig. 2</a>). Heterogeneity was not statistically significant (<em>P</em> = .82 and <em>I</em><sup>2</sup> = 0%). A funnel plot analysis revealed statistically significant asymmetry (<em>P</em>&lt;.001), suggesting that negative results (i.e., fewer thrombo-embolic events in the treated group) were underreported. We
                  did not detect statistically significant differences in relative risks for a thrombo-embolic event among various subgroups
                  as defined by prespecified variables. Absolute risk and the number needed to harm vary with the underlying risk of specific
                  cancer populations. With an underlying risk of 1.5%, the number needed to harm is 99.5 (95% CI = 62.9 to 190.5), indicating
                  that for every 100 patients treated with epoetin to darbepoetin, about one additional patient would experience a thrombo-embolic
                  event. With a baseline risk of 20%, the number needed to harm is 7.5 (95% CI = 3.1 to 15.6).
                  
               </p>
               <div id="F2" class="fig pos-float odd">
                  <div class="fig-inline"><a href="708/F2.expansion.html"><img alt="Fig. 2." src="708/F2.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                           <li><a href="708/F2.expansion.html">In this window</a></li>
                           <li><a class="in-nw" href="708/F2.expansion.html">In a new window</a></li>
                        </ul>
                        <ul class="fig-services">
                           <li class="ppt-link"><a href="/powerpoint/98/10/708/F2">Download as PowerPoint Slide</a></li>
                        </ul>
                     </div>
                  </div>
                  <div class="fig-caption"><span class="fig-label"><strong>Fig. 2.</strong></span> 
                     <p id="p-9" class="first-child">Meta-analysis of the relative risk (RR) for thrombo-embolic complications in cancer patients receiving epoetin or darbepoetin
                        or standard care. <strong>Solid squares</strong> represent risk estimates for the single studies. The size of the squares is proportional to the sample size and the number
                        of events. <strong>Horizontal lines</strong> denote 95% confidence intervals (CIs). The <strong>diamond</strong> shows the confidence interval for the pooled relative risks. Positive values indicate a relative risk increase for thrombo-embolic
                        complications in patients receiving epoetin or darbepoetin. Test for overall effect: <em>Z</em> = 4.76, <em>P</em>&lt;.001; test for heterogeneity chi-square = 26.52, degrees of freedom = 34, <em>P</em> = .82; <em>I</em><sup>2</sup> = 0%. J&amp;J refers to data that were taken from the Johnson &amp; Johnson briefing document, Roche refers to the Roche briefing
                        document, and FDA refers to briefing documents prepared by U.S. Food and Drug Administration (FDA) reviewers presented at
                        the FDA Oncology Drugs Advisory Committee hearing on May 4, 2004 <em>(<a id="xref-ref-10-2" class="xref-bibr" href="#ref-10">10</a>)</em>. Thatcher 1999a <em>(<a id="xref-ref-37-1" class="xref-bibr" href="#ref-37">37</a>)</em> = patients in treatment arm received 150 IU/kg three times a week; Thatcher 1999b <em>(<a id="xref-ref-37-2" class="xref-bibr" href="#ref-37">37</a>)</em> = patients in treatment arm received 300 IU/kg three times a week; Ten Bokkel 1998a <em>(<a id="xref-ref-31-1" class="xref-bibr" href="#ref-31">31</a>)</em> = patients in treatment arm received 150 IU/kg three times a week; Ten Bokkel 1998b <em>(<a id="xref-ref-31-2" class="xref-bibr" href="#ref-31">31</a>)</em> = patients in treatment arm received 300 IU/kg three times a week; Österborg 1996a <em>(<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a>)</em> = patients in treatment arm received 10 000 IU daily; Österborg 1996b <em>(<a id="xref-ref-24-2" class="xref-bibr" href="#ref-24">24</a>)</em> = patients in treatment arm received 2000 IU daily, and if the level of hemoglobin did not increase after 8 weeks, the dose
                        was increased to 5000 IU and to 10 000 IU daily after 12 weeks.
                     </p>
                     <div class="sb-div caption-clear"></div>
                  </div>
               </div>
               <p id="p-10">Overall survival was investigated for 8167 patients from 42 studies. The nonstatistically significant pooled hazard ratio
                  (HR = 1.08, 95% CI = 0.99 to 1.18) indicates that survival was not improved by treatment with epoetin or darbepoetin and raises
                  the possibility that survival may be decreased among patients treated with epoetin or darbepoetin. Heterogeneity was not statistically
                  significant (<em>P</em> = .27 and <em>I</em><sup>2</sup> = 11.5%) (<a id="xref-fig-3-1" class="xref-fig" href="#F3">Fig. 3</a>). Data appeared symmetrical in funnel plot analysis (<em>P</em> = .35). Data analysis used individual patient data <em>(<a id="xref-ref-34-1" class="xref-bibr" href="#ref-34">34</a>)</em>, aggregated time-to-event data [21 studies <em>(<a id="xref-ref-6-3" class="xref-bibr" href="#ref-6">6</a>–<a id="xref-ref-8-3" class="xref-bibr" href="#ref-8">8</a>,<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>,<a id="xref-ref-15-3" class="xref-bibr" href="#ref-15">15</a>–<a id="xref-ref-17-3" class="xref-bibr" href="#ref-17">17</a>,<a id="xref-ref-19-2" class="xref-bibr" href="#ref-19">19</a>,<a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a>,<a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">23</a>,<a id="xref-ref-24-3" class="xref-bibr" href="#ref-24">24</a>,<a id="xref-ref-31-3" class="xref-bibr" href="#ref-31">31</a>,<a id="xref-ref-39-2" class="xref-bibr" href="#ref-39">39</a>,<a id="xref-ref-42-1" class="xref-bibr" href="#ref-42">42</a>,<a id="xref-ref-46-1" class="xref-bibr" href="#ref-46">46</a>,<a id="xref-ref-53-1" class="xref-bibr" href="#ref-53">53</a>,<a id="xref-ref-54-1" class="xref-bibr" href="#ref-54">54</a>,<a id="xref-ref-57-1" class="xref-bibr" href="#ref-57">57</a>,<a id="xref-ref-64-1" class="xref-bibr" href="#ref-64">64</a>,<a id="xref-ref-65-1" class="xref-bibr" href="#ref-65">65</a>,<a id="xref-ref-67-1" class="xref-bibr" href="#ref-67">67</a>)</em>]<em></em>, or the number of deaths [20 studies <em>(<a id="xref-ref-12-3" class="xref-bibr" href="#ref-12">12</a>,<a id="xref-ref-14-2" class="xref-bibr" href="#ref-14">14</a>,<a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">22</a>,<a id="xref-ref-27-2" class="xref-bibr" href="#ref-27">27</a>,<a id="xref-ref-32-1" class="xref-bibr" href="#ref-32">32</a>,<a id="xref-ref-35-1" class="xref-bibr" href="#ref-35">35</a>,<a id="xref-ref-37-3" class="xref-bibr" href="#ref-37">37</a>,<a id="xref-ref-41-1" class="xref-bibr" href="#ref-41">41</a>,<a id="xref-ref-43-1" class="xref-bibr" href="#ref-43">43</a>–<a id="xref-ref-45-1" class="xref-bibr" href="#ref-45">45</a>,<a id="xref-ref-47-1" class="xref-bibr" href="#ref-47">47</a>,<a id="xref-ref-48-1" class="xref-bibr" href="#ref-48">48</a>,<a id="xref-ref-51-1" class="xref-bibr" href="#ref-51">51</a>,<a id="xref-ref-55-1" class="xref-bibr" href="#ref-55">55</a>,<a id="xref-ref-56-1" class="xref-bibr" href="#ref-56">56</a>,<a id="xref-ref-61-1" class="xref-bibr" href="#ref-61">61</a>–<a id="xref-ref-63-1" class="xref-bibr" href="#ref-63">63</a>,<a id="xref-ref-66-2" class="xref-bibr" href="#ref-66">66</a>)</em>]. Only seven of the included trials were specifically designed to measure overall or progression-free survival; pooled data
                  from these seven studies with 2188 patients resulted in a pooled hazard ratio of 1.16 (95% CI = 1.01 to 1.33). Another six
                  studies with 1661 patients were stopped prematurely (HR = 1.34, 95% CI = 1.12 to 1.61). No robust statistically significant
                  associations were found for any subgroup explored.
                  
               </p>
               <div id="F3" class="fig pos-float odd">
                  <div class="fig-inline"><a href="708/F3.expansion.html"><img alt="Fig. 3." src="708/F3.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                           <li><a href="708/F3.expansion.html">In this window</a></li>
                           <li><a class="in-nw" href="708/F3.expansion.html">In a new window</a></li>
                        </ul>
                        <ul class="fig-services">
                           <li class="ppt-link"><a href="/powerpoint/98/10/708/F3">Download as PowerPoint Slide</a></li>
                        </ul>
                     </div>
                  </div>
                  <div class="fig-caption"><span class="fig-label"><strong>Fig. 3.</strong></span> 
                     <p id="p-11" class="first-child">Meta-analysis of the hazard ratio (HR) for overall survival for cancer patients receiving epoetin or darbepoetin or standard
                        care. <strong>Solid squares</strong> represent risk estimates for the single studies. The size of the squares is proportional to the sample size and the number
                        of events. <strong>Horizontal lines</strong> denote 95% confidence intervals (CIs). The <strong>diamond</strong> shows the confidence interval for the pooled hazard ratio. Positive values indicate a hazard ratio increase for patients
                        receiving epoetin or darbepoetin. Test for overall effect: <em>Z</em> = 1.63, <em>P</em> = .10; test for heterogeneity chi-square = 44.04, degrees of freedom = 39, <em>P</em> = .27; and <em>I</em><sup>2</sup> = 11.5%. J&amp;J refers to data that were taken from the Johnson &amp; Johnson briefing document, Roche and Roc refer to the Roche
                        briefing document, Am. refers to the Amgen briefing document, and FDA refers to briefing documents prepared by U.S. Food and
                        Drug Administration (FDA) reviewers presented at the FDA Oncology Drugs Advisory Committee hearing on May 4, 2004 <em>(<a id="xref-ref-10-3" class="xref-bibr" href="#ref-10">10</a>)</em>. Thatcher 1999a <em>(<a id="xref-ref-37-4" class="xref-bibr" href="#ref-37">37</a>)</em> = patients in treatment arm received 150 IU/kg three times a week; Thatcher 1999b <em>(<a id="xref-ref-37-5" class="xref-bibr" href="#ref-37">37</a>)</em> = patients in treatment arm received 300 IU/kg three times a week.
                     </p>
                     <div class="sb-div caption-clear"></div>
                  </div>
               </div>
               <p id="p-12">Results of this update confirm earlier findings on hematologic and transfusion outcomes <em>(<a id="xref-ref-3-3" class="xref-bibr" href="#ref-3">3</a>,<a id="xref-ref-4-2" class="xref-bibr" href="#ref-4">4</a>)</em>. Although the first review indicated that treatment with epoetin, compared with no treatment, might be associated with increased
                  survival (adjusted HR = 0.81, 95% CI = 0.67 to 0.99; unadjusted HR = 0.84, 95% CI = 0.69 to 1.02), the updated analysis found
                  no association between treatment and survival and possibly even that decreased survival might be associated with treatment
                  (HR = 1.08, 95% CI = 0.99 to 1.18). This change in direction for the point estimate reflects results reported by studies published
                  since January 1, 2002, which indicated that treatment, compared with no treatment, was associated with decreased survival
                  (HR = 1.16, 95% CI = 1.04 to 1.29). Compared with the studies in the first review, trials in the updated review tended to
                  enroll patients with higher baseline hemoglobin levels and patients who used higher doses of epoetin or darbepoetin and to
                  target hemoglobin levels that were higher than 13 g/dL to maintain high hemoglobin levels in nonanemic cancer patients.
               </p>
               <p id="p-13">Although the previous review indicated that epoetin treatment was not statistically significantly associated with an increased
                  risk for thrombo-embolic events (RR = 1.58, 95% CI = 0.94 to 2.66), we found, in the updated review, that this association
                  was strengthened and became statistically significant (RR = 1.67, 95% CI = 1.35 to 2.06). The apparent excess of thrombo-embolic
                  events observed in several trials that enrolled nonanemic patients and/or targeted hemoglobin levels higher than product label
                  recommendations raises concerns that the relationship may be causal <em>(<a id="xref-ref-9-2" class="xref-bibr" href="#ref-9">9</a>)</em>. In a phase III randomized study of 939 patients with advanced breast cancer undergoing chemotherapy <em>(<a id="xref-ref-8-4" class="xref-bibr" href="#ref-8">8</a>,<a id="xref-ref-68-1" class="xref-bibr" href="#ref-68">68</a>)</em>, treatment with epoetin alfa to maintain hemoglobin levels between 12 and 14 g/dL was associated with higher rates of fatal
                  thrombo-embolic events than placebo [1.3% versus 0.6% for placebo <em>(<a id="xref-ref-68-2" class="xref-bibr" href="#ref-68">68</a>)</em>]. In a phase III trial with 351 head and neck cancer patients undergoing radiotherapy, the rate of death from cardiac disorder
                  was greater among patients randomly assigned to receive epoetin beta to maintain a hemoglobin level between 12 and 14 g/dL
                  for women or between 13 and 15 g/dL for men (5.5% versus 3% for patients who received placebo) <em>(<a id="xref-ref-7-2" class="xref-bibr" href="#ref-7">7</a>)</em>. The high hemoglobin level at the study's end (i.e., male participants with 15.4 g/dL) might have contributed to the many
                  thrombo-embolic events observed.
               </p>
               <p id="p-14">A limitation of our study was that, with the available data, we could not detect a statistically significant association between
                  the relative risk for thrombo-embolic events and hemoglobin level at baseline or other factors evaluated, perhaps, in part,
                  because of the lack of standard definitions of venous thrombo-embolism. Events within trials were possibly underreported because
                  no prospective and uniform screening protocol for thrombo-embolic events was included in the clinical trials. Specific individual
                  patient data on hemoglobin levels preceding a thrombo-embolic event would be necessary to clarify a possible association between
                  hemoglobin level and thrombo-embolic events. Although the lack of a statistically significant association in the available
                  data does not exclude a causal relationship, recombinant erythropoietins may be thrombogenic by mechanisms that are independent
                  of hemoglobin levels. A retrospective case-control study in cervical cancer patients with concurrent chemotherapy and radiotherapy
                  and a prospective observational study in ambulatory cancer patients provide some support for this possibility <em>(<a id="xref-ref-69-1" class="xref-bibr" href="#ref-69">69</a>,<a id="xref-ref-70-1" class="xref-bibr" href="#ref-70">70</a>)</em>.
               </p>
               <p id="p-15">Although more frequent thrombo-embolic events may contribute to reduced survival of patients treated with epoetin or darbepoetin
                  in more recent trials, hypothesized effects on tumor growth may also affect survival. Preclinical studies have reported high
                  levels of erythropoietin receptors in breast cancer cells and other malignant cells <em>(<a id="xref-ref-71-1" class="xref-bibr" href="#ref-71">71</a>–<a id="xref-ref-75-1" class="xref-bibr" href="#ref-75">75</a>)</em>. Consequently, endogenously produced or exogenously administered erythropoietin might stimulate proliferation of cancer cells
                  that express erythropoietin receptors.
               </p>
               <p id="p-16">Two phase III studies, one in patients with head and neck cancer <em>(<a id="xref-ref-7-3" class="xref-bibr" href="#ref-7">7</a>)</em> and the other in patients with breast cancer <em>(<a id="xref-ref-8-5" class="xref-bibr" href="#ref-8">8</a>,<a id="xref-ref-68-3" class="xref-bibr" href="#ref-68">68</a>),</em> found that poorer response rates and higher death rates were associated with epoetin treatment than with placebo. Henke et
                  al. <em>(<a id="xref-ref-7-4" class="xref-bibr" href="#ref-7">7</a>)</em> reported more frequent tumor progression associated with epoetin beta treatment (for locoregional tumor progression, RR =
                  1.69, 95% CI = 1.16 to 2.47; <em>P</em> = .007). In the study reported by Leyland-Jones et al. <em>(<a id="xref-ref-8-6" class="xref-bibr" href="#ref-8">8</a>,<a id="xref-ref-68-4" class="xref-bibr" href="#ref-68">68</a>)</em>, the observed difference in survival (at 12 months, 70% versus 76%; <em>P</em> = .01) was partly attributed to increased disease progression in the epoetin beta group (at 4 months, 6% versus 3%). However,
                  other phase III studies <em>(<a id="xref-ref-54-2" class="xref-bibr" href="#ref-54">54</a>,<a id="xref-ref-76-1" class="xref-bibr" href="#ref-76">76</a>,<a id="xref-ref-77-1" class="xref-bibr" href="#ref-77">77</a>)</em> in head and neck or breast cancer patients did not observe poorer survival in the epoetin arms, and studies <em>(<a id="xref-ref-78-1" class="xref-bibr" href="#ref-78">78</a>,<a id="xref-ref-79-1" class="xref-bibr" href="#ref-79">79</a>)</em> in pelvic and cervical cancer patients indicated improved tumor control associated with epoetin treatment. The studies reported
                  by Henke et al. and Leyland-Jones et al. had several methodologic limitations, including baseline imbalances <em>(<a id="xref-ref-8-7" class="xref-bibr" href="#ref-8">8</a>)</em> and protocol violations <em>(<a id="xref-ref-7-5" class="xref-bibr" href="#ref-7">7</a>)</em>. Thus, despite intensive reanalyses, the exact causes of poorer survival associated with epoetin treatment in these studies
                  remain uncertain.
               </p>
               <p id="p-17">In view of these uncertainties, treatment with epoetin or darbepoetin to target hemoglobin levels beyond that of anemia (i.e.,
                  &gt;12 g/dL) among cancer patients is potentially harmful and should be considered only in an experimental setting. Caution is
                  advised when using epoetin or darbepoetin in combination with chemotherapeutic agents that are known to be thrombogenic or
                  for cancer patients who are at high risk for thrombo-embolic events.
               </p>
               <div class="section fn-group" id="fn-group-1">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Footnotes</h2>
                  <ul>
                     <li class="fn" id="fn-1">
                        
                        <p id="p-18"><em>Editor's note:</em> Dr. Djulbegovic has received research grants from Amgen and Ortho, the last in 2004. Dr. Bennett's research is sponsored
                           by Amgen.
                        </p>
                        
                     </li>
                     <li class="fn" id="fn-2">
                        
                        <p id="p-19">We thank all authors and investigators who provided us with additional information and the consumers and editors of the Cochrane
                           Hematological Malignancies Group for strong support. The Cochrane Haematological Malignancies Group is part of the Competence
                           Network Malignant Lymphomas and funded by the German Ministry of Education and Research and the German Aerospace Center. The
                           study sponsors had no role in the collection or analysis of the data, the decision to submit the study for publication, or
                           the writing of the manuscript.
                        </p>
                        
                     </li>
                  </ul>
               </div>
               <ul>
                  <li class="fn" id="copyright-statement-1">© The Author 2006. Published by Oxford University Press.</li>
               </ul>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#fn-group-1" title="Footnotes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2>References</h2>
                  <ol class="cit-list ref-use-labels">
                     <li><span class="ref-label">(1)</span><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference (1) in text"
                           id="ref-1">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.1"
                             data-doi="10.1093/jnci/93.16.1204">
                           <div class="cit-metadata"><cite>Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, et al. Epoetin treatment of anemia associated with
                                 cancer therapy: a systematic review and meta-analysis of controlled clinical trials. <span class="cit-source">J Natl Cancer Inst</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">93</span>:<span class="cit-fpage">1204</span>–14.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=93/16/1204"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(2)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.2"
                             data-doi="10.1186/1471-2407-2-23">
                           <div class="cit-metadata"><cite>Clark O, Adams JR, Bennett CL, Djulbegovic B. Erythropoietin, uncertainty principle and cancer related anaemia. <span class="cit-source">BMC Cancer</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">2</span>:<span class="cit-fpage">23</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1186/1471-2407-2-23&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12270068&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(3)</span><a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference (3) in text"
                           id="ref-3">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.3">
                           <div class="cit-metadata"><cite>Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, et al. Erythropoietin for patients with malignant
                                 disease. <span class="cit-source">Cochrane Libr</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">4</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(4)</span><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference (4) in text"
                           id="ref-4">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.4"
                             data-doi="10.1093/jnci/dji087">
                           <div class="cit-metadata"><cite>Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, et al. Recombinant human erythropoietin and overall
                                 survival in cancer patients: results of a comprehensive meta-analysis. <span class="cit-source">J Natl Cancer Inst</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">97</span>:<span class="cit-fpage">489</span>–98.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=97/7/489"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(5)</span><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference (5) in text"
                           id="ref-5">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.5">
                           <div class="cit-metadata"><cite>Quirt I, Bramwell V, Charette M, Oliver T, and the Systemic Treatment Disease Site Group. The role of erythropoietin in the
                                 management of cancer patients with non-hematologic malignancies receiving chemotherapy. Practice Guideline Report #12–1. Report
                                 #12–1; <span class="cit-pub-date">2005</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(6)</span><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference (6) in text"
                           id="ref-6">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.6">
                           <div class="cit-metadata"><cite>Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality
                                 of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
                                 <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">19</span>:<span class="cit-fpage">2865</span>–74.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=19/11/2865"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(7)</span><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference (7) in text"
                           id="ref-7">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.7"
                             data-doi="10.1016/S0140-6736(03)14567-9">
                           <div class="cit-metadata"><cite>Henke M, Laszig R, Ruebe C, Schaefer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients
                                 with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. <span class="cit-source">Lancet</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">362</span>:<span class="cit-fpage">1255</span>–60.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(03)14567-9&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=14575968&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000186036900007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(8)</span><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference (8) in text"
                           id="ref-8">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.8"
                             data-doi="10.1016/S1470-2045(03)01163-X">
                           <div class="cit-metadata"><cite>Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. <span class="cit-source">Lancet Oncol</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">4</span>:<span class="cit-fpage">459</span>–60.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(03)01163-X&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12901958&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000184732200013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(9)</span><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference (9) in text"
                           id="ref-9">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.9">
                           <div class="cit-metadata"><cite>Luksenburg H, Weir A, Wager R. FDA Briefing Document. Safety concerns associated with Aranesp (darbepoetin alfa) Amgen, Inc.
                                 and Procrit (epoetin alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy: hearings
                                 before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services
                                 Food and Drug Administration Center for Drug Evaluation and Research. May 4, <span class="cit-pub-date">2004</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(10)</span><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference (10) in text"
                           id="ref-10">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.10">
                           <div class="cit-metadata"><cite>Food and Drug Administration. Oncologic Drugs Advisory Committee. Available at: <a href="http://www.fda.gov/ohrms/dockets/ac/04/slides/4037s2.htm">http://www.fda.gov/ohrms/dockets/ac/04/slides/4037s2.htm</a>. [Last accessed: March 15, <span class="cit-pub-date">2006</span>.] Available at: <a href="http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037b2.htm">http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037b2.htm</a>. [Last accessed: March 15, 2006.]</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(11)</span><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference (11) in text"
                           id="ref-11">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.11"
                             data-doi="10.1002/(SICI)1097-0258(19981230)17:24&lt;2815::AID-SIM110&gt;3.0.CO;2-8">
                           <div class="cit-metadata"><cite>Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival
                                 endpoints. <span class="cit-source">Stat Med</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">17</span>:<span class="cit-fpage">2815</span>–34.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/(SICI)1097-0258(19981230)17:24%3C2815::AID-SIM110%3E3.0.CO;2-8&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9921604&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000077527600003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(12)</span><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference (12) in text"
                           id="ref-12">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.12">
                           <div class="cit-metadata"><cite>Cascinu S, Fedeli A, Del Ferro E, Fedeli SL, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated
                                 anemia: a randomized, double-blind trial with placebo. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1994</span>;<span class="cit-vol">12</span>:<span class="cit-fpage">1058</span>–62.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=12/5/1058"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(13)</span><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference (13) in text"
                           id="ref-13">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.13"
                             data-doi="10.1093/jnci/85.10.801">
                           <div class="cit-metadata"><cite>Case DC Jr, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, et al. Recombinant human erythropoietin therapy for
                                 anemic cancer patients on combination chemotherapy. <span class="cit-source">J Natl Cancer Inst</span> <span class="cit-pub-date">1993</span>;<span class="cit-vol">85</span>:<span class="cit-fpage">801</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=85/10/801"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(14)</span><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference (14) in text"
                           id="ref-14">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.14">
                           <div class="cit-metadata"><cite>Henry DH, Brooks BJ Jr, Case DC Jr, Fishkin E, Jacobson R, Keller AM, et al. Recombinant human erythropoietin therapy for
                                 anemic cancer patients receiving cisplatin chemotherapy. <span class="cit-source">Cancer J Sci Am</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">1</span>:<span class="cit-fpage">252</span>–60.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=9166485&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(15)</span><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference (15) in text"
                           id="ref-15">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.15">
                           <div class="cit-metadata"><cite>Abels R. Erythropoietin for anemia in cancer patients. <span class="cit-source">Eur J Cancer</span> <span class="cit-pub-date">1993</span>;<span class="cit-vol">29a</span>(Suppl 2):<span class="cit-fpage">2</span>–8.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(16)</span><a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference (16) in text"
                           id="ref-16">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.16">
                           <div class="cit-metadata"><cite>Hearings before the SubCommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and
                                 Human Services Food and Drug Administration Center for Drug Evaluation and Research. P-174. May 4, <span class="cit-pub-date">2004</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(17)</span><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference (17) in text"
                           id="ref-17">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.17">
                           <div class="cit-metadata"><cite>Rose E, Rai K, Revicki D, Brown R, Reblando J. Clinical and health status assessments in anemic chronic lymphocytic leukemia
                                 (CLL) patients treated with epoetin alfa (EPO). <span class="cit-source">Blood</span> <span class="cit-pub-date">1994</span>;<span class="cit-vol">84</span>(10 Suppl 1):<span class="cit-fpage">526a</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(18)</span><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference (18) in text"
                           id="ref-18">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.18" data-doi="10.2307/1390807">
                           <div class="cit-metadata"><cite>Ihaka R, Gentleman R. R: a language for data analysis and graphics. <span class="cit-source">J Comput Graph Stat</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">5</span>:<span class="cit-fpage">299</span>–314.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.2307/1390807&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(19)</span><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference (19) in text"
                           id="ref-19">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.19">
                           <div class="cit-metadata"><cite>Coiffier B, Boogaerts M, Kainz C. Impact of epoetin beta versus standard care on quality of life in patients with malignant
                                 disease. June 21, 2001. 6th Congress of the European Haematology Association, June 21–24, <span class="cit-pub-date">2001</span>, Frankfurt, Germany, Abstract #194.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(20)</span><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference (20) in text"
                           id="ref-20">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.20"
                             data-doi="10.1046/j.1365-2141.2001.02715.x">
                           <div class="cit-metadata"><cite>Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. <span class="cit-source">Br J Haematol</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">113</span>:<span class="cit-fpage">172</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1046/j.1365-2141.2001.02715.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11328297&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000168700500027&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(21)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.21"
                             data-doi="10.1046/j.1365-2141.1998.01085.x">
                           <div class="cit-metadata"><cite>Italian Cooperative Study Group. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin
                                 in patients with low-risk myelodysplastic syndromes. <span class="cit-source">Br J Haematol</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">103</span>:<span class="cit-fpage">1070</span>–4.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1046/j.1365-2141.1998.01085.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9886322&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000077834400025&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(22)</span><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference (22) in text"
                           id="ref-22">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.22"
                             data-doi="10.1006/gyno.1997.4675">
                           <div class="cit-metadata"><cite>Kurz C, Marth C, Windbichler G, Lahousen M, Medl M, Vavra N, et al. Erythropoietin treatment under polychemotherapy in patients
                                 with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. <span class="cit-source">Gynecol Oncol</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">65</span>:<span class="cit-fpage">461</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1006/gyno.1997.4675&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9190976&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1997XE19500018&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(23)</span><a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference (23) in text"
                           id="ref-23">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.23"
                             data-doi="10.1023/A:1008296622469">
                           <div class="cit-metadata"><cite>Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, et al. Recombinant human erythropoietin in the treatment of
                                 chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled
                                 study. <span class="cit-source">Ann Oncol</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">9</span>:<span class="cit-fpage">255</span>–60.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=9/3/255"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(24)</span><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference (24) in text"
                           id="ref-24">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.24">
                           <div class="cit-metadata"><cite>Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, et al. Recombinant human erythropoietin in transfusion-dependent
                                 anemic patients with multiple myeloma and non-Hodgkin's lymphoma—a randomized multicenter study. <span class="cit-source">Blood</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">87</span>:<span class="cit-fpage">2675</span>–82.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bloodjournal&amp;resid=87/7/2675"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(25)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.25"
                             data-doi="10.1200/JCO.2002.08.131">
                           <div class="cit-metadata"><cite>Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, et al. Randomized, double-blind, placebo-controlled
                                 trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">20</span>:<span class="cit-fpage">2486</span>–94.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=20/10/2486"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(26)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.26">
                           <div class="cit-metadata"><cite>Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F. Long-term therapy with recombinant human erythropoietin (rHu-EPO)
                                 in progressing multiple myeloma. <span class="cit-source">Ann Hematol</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">70</span>:<span class="cit-fpage">313</span>–8.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7632811&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995RM62700005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(27)</span><a class="rev-xref-ref" href="#xref-ref-27-1" title="View reference (27) in text"
                           id="ref-27">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.27">
                           <div class="cit-metadata"><cite>Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, et al. Effect of recombinant human erythropoietin
                                 combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome.
                                 <span class="cit-source">Blood</span> <span class="cit-pub-date">2000</span>;<span class="cit-vol">95</span>:<span class="cit-fpage">1175</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bloodjournal&amp;resid=95/4/1175"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(28)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.28">
                           <div class="cit-metadata"><cite>Carabantes FJ, Benavides M, Trujillo R, Cobo M, Hebrero ML, Garcia S, et al. Epoetin alfa in the prevention of anemia in cancer
                                 patients undergoing platinum-based chemotherapy (CT). A prospective randomized study. Proceedings of ASCO. <span class="cit-pub-date">1999</span>. 35th Annual Meeting of the American Society of Clinical Oncology, May 15–18, 1999, Atlanta, GA. Abstract 18, 596a.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(29)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.29"
                             data-doi="10.1016/S0167-8140(98)00115-7">
                           <div class="cit-metadata"><cite>Henke M, Guttenberger R, Barke A, Pajonk F, Potter R, Frommhold H. Erythropoietin for patients undergoing radiotherapy: a
                                 pilot study. <span class="cit-source">Radiother Oncol</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">50</span>:<span class="cit-fpage">185</span>–90.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0167-8140(98)00115-7&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10368042&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000079523900008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(30)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.30">
                           <div class="cit-metadata"><cite>Quirt I, Micucci S, Moran LA, Pater J, Browman G. The role of recombinant human erythropoietin (EPO) in reducing red blood
                                 cell transfusions and maintaining quality of life (QOL) in patients with lymphoma and solid tumors receiving cytotoxic chemotherapy.
                                 Results of a randomized, double-blind, placebo-controlled clinical trial. <span class="cit-source">Blood</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">88</span>[10 (Suppl 1)]:<span class="cit-fpage">347</span> (abstract 1378).</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(31)</span><a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference (31) in text"
                           id="ref-31">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.31"
                             data-doi="10.1007/BF02821936">
                           <div class="cit-metadata"><cite>Ten Bokkel Huinink WW, De Swart CA, Van Toorn DW, Morack G, Breed WP, Hillen HF, et al. Controlled multicentre study of the
                                 influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian
                                 carcinoma treated with platinum-based chemotherapy. <span class="cit-source">Med Oncol</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">15</span>:<span class="cit-fpage">174</span>–82.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1007/BF02821936&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9819794&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000079462700005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(32)</span><a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference (32) in text"
                           id="ref-32">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.32">
                           <div class="cit-metadata"><cite>Throuvalas NA, Antonadou D, Boufi M, Lavey R, et al. Erythropoietin decreases transfusion requirements during radiochemotherapy.
                                 Proceedings of ASCO. <span class="cit-pub-date">2000</span>. 36th Annual Meeting of the American Society of Clinical Oncology, May 20–24, 2000, New Orleans, LA. Abstract 1558.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(33)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.33"
                             data-doi="10.1046/j.1537-2995.1996.36296181929.x">
                           <div class="cit-metadata"><cite>Wurnig C, Windhager R, Schwameis E, Kotz R, et al. Prevention of chemotherapy-induced anemia by the use of erythropoietin
                                 in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). <span class="cit-source">Transfusion</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">36</span>:<span class="cit-fpage">155</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1046/j.1537-2995.1996.36296181929.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8614967&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1996TX29700013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(34)</span><a class="rev-xref-ref" href="#xref-ref-34-1" title="View reference (34) in text"
                           id="ref-34">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.34">
                           <div class="cit-metadata"><cite>Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, et al. Randomized phase III trial evaluating the
                                 role of erythropoietin in the prevention of chemotherapy-induced anemia. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">15</span>:<span class="cit-fpage">2715</span>–21.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=15/7/2715"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(35)</span><a class="rev-xref-ref" href="#xref-ref-35-1" title="View reference (35) in text"
                           id="ref-35">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.35"
                             data-doi="10.1002/(SICI)1097-0142(19991001)86:7&lt;1362::AID-CNCR36&gt;3.0.CO;2-T">
                           <div class="cit-metadata"><cite>Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG, Boyd JH. Erythropoietin reduces anemia and transfusions. <span class="cit-source">Cancer</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">86</span>:<span class="cit-fpage">1362</span>–7.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/(SICI)1097-0142(19991001)86:7%3C1362::AID-CNCR36%3E3.0.CO;2-T&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10506726&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000082749200036&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(36)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.36"
                             data-doi="10.1007/s10147-001-8031-y">
                           <div class="cit-metadata"><cite>Kunikane H, Watanabe K, Fukuoka M, Saijo N, Furuse K, Ikegami H, et al. Double-blind randomized control trial of the effect
                                 of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. <span class="cit-source">Int J Clin Oncol</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">6</span>:<span class="cit-fpage">296</span>–301.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1007/s10147-001-8031-y&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11828949&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(37)</span><a class="rev-xref-ref" href="#xref-ref-37-1" title="View reference (37) in text"
                           id="ref-37">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.37"
                             data-doi="10.1038/sj.bjc.6690369">
                           <div class="cit-metadata"><cite>Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, et al. Epoetin alpha prevents anaemia and reduces transfusion
                                 requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. <span class="cit-source">Br J Cancer</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">80</span>:<span class="cit-fpage">396</span>–402.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/sj.bjc.6690369&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10408844&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000080028900013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(38)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.38">
                           <div class="cit-metadata"><cite>Welch RS, James RD, Wilkinson PM. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
                                 <span class="cit-source">Cancer J Sci Am</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">1</span>:<span class="cit-fpage">261</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=9166486&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(39)</span><a class="rev-xref-ref" href="#xref-ref-39-1" title="View reference (39) in text"
                           id="ref-39">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.39">
                           <div class="cit-metadata"><cite>Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller Ziegler L, et al. Recombinant human erythropoietin in the anemia
                                 associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. <span class="cit-source">Blood</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">86</span>:<span class="cit-fpage">4446</span>–53.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bloodjournal&amp;resid=86/12/4446"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(40)</span><a class="rev-xref-ref" href="#xref-ref-40-1" title="View reference (40) in text"
                           id="ref-40">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.40">
                           <div class="cit-metadata"><cite>Aravantinos G, Linardou H, Makridaki D, Laiou E, Zafiropoulos A, Janninis J, et al. Recombinant human erythropoietin for platinum-based
                                 chemotherapy-induced anaemia: a single-centre randomised study. <span class="cit-source">J Balkan Union Oncol</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">8</span>:<span class="cit-fpage">127</span>–32.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(41)</span><a class="rev-xref-ref" href="#xref-ref-41-1" title="View reference (41) in text"
                           id="ref-41">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.41"
                             data-doi="10.1046/j.1365-2141.2002.03774.x">
                           <div class="cit-metadata"><cite>Hedenus M, Hansen S, Taylor K, Arthur C, Emmerich D, Dewey C, et al. Randomized, dose-finding study of darbepoetin alfa in
                                 anaemic patients with lymphoproliferative malignancies. <span class="cit-source">Br J Haematol</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">119</span>:<span class="cit-fpage">79</span>–86.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1046/j.1365-2141.2002.03774.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12358906&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000178348000011&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(42)</span><a class="rev-xref-ref" href="#xref-ref-42-1" title="View reference (42) in text"
                           id="ref-42">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.42"
                             data-doi="10.1046/j.1365-2141.2003.04448.x">
                           <div class="cit-metadata"><cite>Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, et al. Efficacy and safety of darbepoetin alfa
                                 in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. <span class="cit-source">Br J Haematol</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">122</span>:<span class="cit-fpage">394</span>–403.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1046/j.1365-2141.2003.04448.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12877666&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000184346000005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(43)</span><a class="rev-xref-ref" href="#xref-ref-43-1" title="View reference (43) in text"
                           id="ref-43">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.43"
                             data-doi="10.1016/S0959-8049(03)00456-8">
                           <div class="cit-metadata"><cite>Kotasek D, Steger G, Faught W, Underhill C, Poulsen E, Colowick AB, et al. Darbepoetin alfa administered every 3 weeks alleviates
                                 anaemia in patients with solid tumours receiving chemotherapy: results of a double-blind, placebo-controlled, randomised study.
                                 <span class="cit-source">Eur J Cancer</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">39</span>:<span class="cit-fpage">2026</span>–34.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0959-8049(03)00456-8&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12957457&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000185510400017&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(44)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.44">
                           <div class="cit-metadata"><cite>Razzouk BI, Hockenberry M, Hinds PS, Rackoff W, Hord JD. A double-blind, placebo-controlled study of once-weekly epoetin alfa
                                 in children with cancer undergoing myelosuppressive chemotherapy. J Clin Oncol 22[14S]. June 5, <span class="cit-pub-date">2004</span>. 40th Annual Meeting of the American Society of Clinical Oncology, June 5–8, 2004, New Orleans, LA. Abstract 8527.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(45)</span><a class="rev-xref-ref" href="#xref-ref-45-1" title="View reference (45) in text"
                           id="ref-45">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.45"
                             data-doi="10.1038/sj.bjc.6600994">
                           <div class="cit-metadata"><cite>Smith RE, Tchekmedyian NS, Chan D, Meza LA, Northfelt DW, Patel R, et al. A dose- and schedule-finding study of darbepoetin
                                 alpha for the treatment of chronic anaemia of cancer. <span class="cit-source">Br J Cancer</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">88</span>:<span class="cit-fpage">1851</span>–8.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/sj.bjc.6600994&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12799626&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000183729200006&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(46)</span><a class="rev-xref-ref" href="#xref-ref-46-1" title="View reference (46) in text"
                           id="ref-46">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.46"
                             data-doi="10.1200/JCO.2004.10.020">
                           <div class="cit-metadata"><cite>Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, et al. Phase III, randomized, double-blind study
                                 of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">23</span>:<span class="cit-fpage">2606</span>–17.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=23/12/2606"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(47)</span><a class="rev-xref-ref" href="#xref-ref-47-1" title="View reference (47) in text"
                           id="ref-47">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.47"
                             data-doi="10.1159/000067766">
                           <div class="cit-metadata"><cite>Bamias A, Aravantinos G, Kalofonos C, Timotheadou N, Siafaka V, Vlahou I, et al. Prevention of anemia in patients with solid
                                 tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): a prospective, open label, randomized
                                 trial by the Hellenic Cooperative Oncology Group. <span class="cit-source">Oncology</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">64</span>:<span class="cit-fpage">102</span>–10.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1159/000067766&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12566906&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000181282900002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(48)</span><a class="rev-xref-ref" href="#xref-ref-48-1" title="View reference (48) in text"
                           id="ref-48">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.48"
                             data-doi="10.1200/JCO.2004.12.027">
                           <div class="cit-metadata"><cite>Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and
                                 reduces transfusion in breast cancer patients receiving chemotherapy. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">23</span>:<span class="cit-fpage">2597</span>–605.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=23/12/2597"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(49)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.49"
                             data-doi="10.1016/S0885-3924(03)00070-8">
                           <div class="cit-metadata"><cite>Iconomou G, Koutras A, Rigopoulos A, Vagenakis AG, Kalofonos HP. Effect of recombinant human erythropoietin on quality of
                                 life in cancer patients receiving chemotherapy: results of a randomized, controlled trial. <span class="cit-source">J Pain Symptom Manage</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">25</span>:<span class="cit-fpage">512</span>–8.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0885-3924(03)00070-8&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12782431&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000183508600005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(50)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.50">
                           <div class="cit-metadata"><cite>Janinis J, Dafni U, Aravantinos G, Kalofonos HP, Papakostas P, Tsavdaridis D, et al. Quality of life (QoL) outcome of epoietin-alfa
                                 (EPO-A) in anemic cancer patients undergoing platinum or non-platinum-based chemotherapy: a randomized study conducted by
                                 the Hellenic Cooperative Oncology Group. Proceedings of ASCO. May 31, <span class="cit-pub-date">2003</span>. 39th Annual Meeting of the American Society of Clinical Oncology, May 31 to June 3, 2003, Chicago, IL. Abstract 3172.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(51)</span><a class="rev-xref-ref" href="#xref-ref-51-1" title="View reference (51) in text"
                           id="ref-51">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.51">
                           <div class="cit-metadata"><cite>Savonije J, Van Groeningen C, Van Bochove A, Pinedo H, Giaccone G. Early intervention with epoetin-alfa during platinum-based
                                 chemotherapy. J Clinical Oncology 22[14S]. June 5, <span class="cit-pub-date">2004</span>. 40th Annual Meeting of the American Society of Clinical Oncology, June 5–8, 2004, New Orleans, LA. Abstract 8111.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(52)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.52">
                           <div class="cit-metadata"><cite>Thomas H, McAdam KF, Thomas RJ, Joffe JK, Sugden EM, Awwad ST, et al. Early intervention with epoetin alfa for treatment of
                                 anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy. Ann Oncol 13(Suppl 5):177.
                                 October 18, <span class="cit-pub-date">2002</span>. 27th European Society for Medical Oncology, 18–22 October 2002, Nice, France. Abstract 653p.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(53)</span><a class="rev-xref-ref" href="#xref-ref-53-1" title="View reference (53) in text"
                           id="ref-53">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.53"
                             data-doi="10.1093/jnci/94.16.1211">
                           <div class="cit-metadata"><cite>Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, et al. Double-blind, placebo-controlled, randomized phase
                                 III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. <span class="cit-source">J Natl Cancer Inst</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">94</span>:<span class="cit-fpage">1211</span>–20.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=94/16/1211"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(54)</span><a class="rev-xref-ref" href="#xref-ref-54-1" title="View reference (54) in text"
                           id="ref-54">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.54">
                           <div class="cit-metadata"><cite>Machtay M, Pajak T, Suntharalingam M, Hershock D, Stripp DC, Cmelak A, et al. Definitive radiotherapy±erythropoietin for squamous
                                 cell carcinoma of the head and neck: preliminary report of RTOG 99–03. Int J Radiat Oncol Biol Phys 60(1 suppl):S132. October
                                 3, <span class="cit-pub-date">2004</span>. Proceedings of the American Society for Therapeutic Radiology and Oncology 46th annual meeting. Georgia World Congress Center,
                                 October 3–7, 2004, Atlanta, GA.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(55)</span><a class="rev-xref-ref" href="#xref-ref-55-1" title="View reference (55) in text"
                           id="ref-55">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.55">
                           <div class="cit-metadata"><cite>O'Shaugnessy J, Vukelja SJ, Holmes FA, Savin M, Jones M, Royall D, et al. Feasibility of quantifying the effects of epoetin
                                 alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. <span class="cit-source">Clin Breast Cancer</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">5</span>:<span class="cit-fpage">439</span>–46.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=15748464&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(56)</span><a class="rev-xref-ref" href="#xref-ref-56-1" title="View reference (56) in text"
                           id="ref-56">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.56">
                           <div class="cit-metadata"><cite>Vadhan-Raj S, Skibber JM, Crane C, Buesos-Ramos CE, Rodriguez-Bigas MA, Feig BW, et al. Randomized, double-blind, placebo-controlled
                                 trial of epoetin alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy (CT/RT) followed
                                 by surgery: early termination of the trial due to increased incidence of thrombo-embolic events (TEE). Blood 104:797a. December
                                 4, <span class="cit-pub-date">2004</span>. 46th Annual Meeting of the American Sociey of Hematology, Dec 4–7, 2004, San Diego, CA. Abstract 2915.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(57)</span><a class="rev-xref-ref" href="#xref-ref-57-1" title="View reference (57) in text"
                           id="ref-57">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.57">
                           <div class="cit-metadata"><cite>Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and
                                 Human Services Food and Drug Administration Center for Drug Evaluation and Research, EPO GBR-07; <span class="cit-pub-date">2004</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(58)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.58">
                           <div class="cit-metadata"><cite>Henze G, Michon J, Morland B, Perek D, Rizzari C, Zoubek A, et al. Phase III randomized study: efficacy of epoetin alfa in
                                 reducing blood transfusions in newly diagnosed pediatric cancer patients receiving chemotherapy. Proceedings of ASCO 21. May
                                 18, <span class="cit-pub-date">2002</span>. 38th Annual Meeting of American Society of Clinical Oncology, May 18–21, 2002 Orlando, FL. Abstract 1547.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(59)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.59"
                             data-doi="10.1093/annonc/mdf657">
                           <div class="cit-metadata"><cite>Huddart RA, Welch RS, Chan S, Perren T, Atkinson R. A prospective randomised comparative-group evaluation of epoetin alfa
                                 for the treatment of anaemia in UK cancer patients receiving platinum-based chemotherapy. <span class="cit-source">Ann Oncol</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">13</span>(Suppl 5):<span class="cit-fpage">177</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=PDF&amp;journalCode=annonc&amp;resid=13/suppl_4/177"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(60)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.60"
                             data-doi="10.1016/j.jpainsymman.2003.06.010">
                           <div class="cit-metadata"><cite>Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM. The decision to prematurely terminate a trial of R-HuEPO due to
                                 thrombotic events. <span class="cit-source">J Pain Symptom Manage</span> <span class="cit-pub-date">2004</span>;<span class="cit-vol">27</span>:<span class="cit-fpage">185</span>–90.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/j.jpainsymman.2003.06.010&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15157043&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000189269400014&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(61)</span><a class="rev-xref-ref" href="#xref-ref-61-1" title="View reference (61) in text"
                           id="ref-61">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.61">
                           <div class="cit-metadata"><cite>Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and
                                 Human Services Food and Drug Administration Center for Drug Evaluation and Research, EPO-CAN-15; <span class="cit-pub-date">2004</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(62)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.62">
                           <div class="cit-metadata"><cite>Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and
                                 Human Services Food and Drug Administration Center for Drug Evaluation and Research, EPO-CAN-20. May 4, <span class="cit-pub-date">2004</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(63)</span><a class="rev-xref-ref" href="#xref-ref-63-1" title="View reference (63) in text"
                           id="ref-63">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.63">
                           <div class="cit-metadata"><cite>Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and
                                 Human Services Food and Drug Administration Center for Drug Evaluation and Research, GOG-191. May 4, <span class="cit-pub-date">2004</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(64)</span><a class="rev-xref-ref" href="#xref-ref-64-1" title="View reference (64) in text"
                           id="ref-64">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.64">
                           <div class="cit-metadata"><cite>Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and
                                 Human Services Food and Drug Administration Center for Drug Evaluation and Research, INT-1, May 4, <span class="cit-pub-date">2004</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(65)</span><a class="rev-xref-ref" href="#xref-ref-65-1" title="View reference (65) in text"
                           id="ref-65">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.65">
                           <div class="cit-metadata"><cite>Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and
                                 Human Services Food and Drug Administration Center for Drug Evaluation and Research, INT-3, May 4, <span class="cit-pub-date">2004</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(66)</span><a class="rev-xref-ref" href="#xref-ref-66-1" title="View reference (66) in text"
                           id="ref-66">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.66">
                           <div class="cit-metadata"><cite>Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and
                                 Human Services Food and Drug Administration Center for Drug Evaluation and Research, N93 004. May 4, <span class="cit-pub-date">2004</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(67)</span><a class="rev-xref-ref" href="#xref-ref-67-1" title="View reference (67) in text"
                           id="ref-67">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.67"
                             data-doi="10.1111/j.1365-2141.2005.05440.x">
                           <div class="cit-metadata"><cite>Osterborg A, Brandberg Y, Hedenus M. Impact of epoetin-b on survival of patients with lymphoproliferative malignanices: long-term
                                 follow up of a large randomized study. <span class="cit-source">Br J Haematol</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">129</span>:<span class="cit-fpage">206</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1111/j.1365-2141.2005.05440.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15813848&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(68)</span><a class="rev-xref-ref" href="#xref-ref-68-1" title="View reference (68) in text"
                           id="ref-68">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.68"
                             data-doi="10.1200/JCO.2005.06.150">
                           <div class="cit-metadata"><cite>Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels
                                 with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival
                                 study. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">23</span>:<span class="cit-fpage">5960</span>–72.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=23/25/5960"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(69)</span><a class="rev-xref-ref" href="#xref-ref-69-1" title="View reference (69) in text"
                           id="ref-69">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.69"
                             data-doi="10.1002/cncr.11700">
                           <div class="cit-metadata"><cite>Wun T, Law L, Harvey D, Sieracki B, Scudder SA, Ryu JK. Increased incidence of symptomatic venous thrombosis in patients with
                                 cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. <span class="cit-source">Cancer</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">98</span>:<span class="cit-fpage">1514</span>–20.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/cncr.11700&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=14508840&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000185464100024&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(70)</span><a class="rev-xref-ref" href="#xref-ref-70-1" title="View reference (70) in text"
                           id="ref-70">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.70"
                             data-doi="10.1002/cncr.21496">
                           <div class="cit-metadata"><cite>Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective
                                 observational study. <span class="cit-source">Cancer</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">104</span>:<span class="cit-fpage">2822</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/cncr.21496&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16284987&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000233880900022&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(71)</span><a class="rev-xref-ref" href="#xref-ref-71-1" title="View reference (71) in text"
                           id="ref-71">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.71">
                           <div class="cit-metadata"><cite>Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, et al. Erythropoietin and erythropietin receptor expression in human
                                 cancer. <span class="cit-source">Cancer Res</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">61</span>:<span class="cit-fpage">3561</span>–5.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=61/9/3561"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(72)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.72"
                             data-doi="10.1097/01.LAB.0000020415.72863.40">
                           <div class="cit-metadata"><cite>Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, et al. Functional significance of erythropoietin receptor expression
                                 in breast cancer. <span class="cit-source">Lab Invest</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">82</span>:<span class="cit-fpage">911</span>–8.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/01.LAB.0000020415.72863.40&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12118093&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000176831200011&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(73)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.73"
                             data-doi="10.1093/carcin/bgg060">
                           <div class="cit-metadata"><cite>Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, et al. Erythropoietin regulates tumour growth of human malignancies.
                                 <span class="cit-source">Carcinogenesis</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">24</span>:<span class="cit-fpage">1021</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=carcin&amp;resid=24/6/1021"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(74)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.74"
                             data-doi="10.1007/s00277-004-0911-6">
                           <div class="cit-metadata"><cite>Jelkmann W, Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. <span class="cit-source">Ann Hematol</span> <span class="cit-pub-date">2004</span>;<span class="cit-vol">83</span>:<span class="cit-fpage">673</span>–86.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1007/s00277-004-0911-6&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15322761&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000224604500001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(75)</span><a class="rev-xref-ref" href="#xref-ref-75-1" title="View reference (75) in text"
                           id="ref-75">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.75">
                           <div class="cit-metadata"><cite>Arcasoy MO, Amin K, Chou SC, Haroon ZA, Varia M, Raleigh JA. Erythropoietin and erythropoietin receptor expression in head
                                 and neck cancer: relationship to tumor hypoxia. <span class="cit-source">Clin Cancer Res</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">11</span>:<span class="cit-fpage">20</span>–7.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=11/1/20"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(76)</span><a class="rev-xref-ref" href="#xref-ref-76-1" title="View reference (76) in text"
                           id="ref-76">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.76">
                           <div class="cit-metadata"><cite>Rosen FR, Haraf DJ, Kies MS, Stenson K, Portugal L, List MA, et al. Multicenter randomized phase II study of paclitaxel (1-hour
                                 infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head
                                 and neck cancer. <span class="cit-source">Clin Cancer Res</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">9</span>:<span class="cit-fpage">1689</span>–97.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=9/5/1689"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(77)</span><a class="rev-xref-ref" href="#xref-ref-77-1" title="View reference (77) in text"
                           id="ref-77">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.77">
                           <div class="cit-metadata"><cite>Michael U, Jackisch C, Lenhard MS, Du Bois A, Lueck H, Thomssen C, et al. Epoetin-alpha reduces red blood cell transfusions
                                 (RBC) in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E), paclitaxel
                                 (T) and cyclophosphamid (C) (ETC). J Clin Oncol. May 13, <span class="cit-pub-date">2005</span>. 41st Annual Meeting of the American Society of Clinical Oncology, May 13–17, 2003, Orlando, FL. Abstract 613.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(78)</span><a class="rev-xref-ref" href="#xref-ref-78-1" title="View reference (78) in text"
                           id="ref-78">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.78">
                           <div class="cit-metadata"><cite>Antonadou D, Cardamakis E, Puglisi M, Malamos N, Throuvalas N. Erythropoietin enhances radiation treatment efficacy in patients
                                 with pelvic malignancies. Final results of a randomized phase III study. <span class="cit-source">Eur J Cancer</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">37</span>(Suppl 6):<span class="cit-fpage">S144</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(79)</span><a class="rev-xref-ref" href="#xref-ref-79-1" title="View reference (79) in text"
                           id="ref-79">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.10.708.79">
                           <div class="cit-metadata"><cite>Blohmer JU, Wurschmidt F, Petry U, Weise G, Sehouli J, Kimming R, et al. Results with sequential adjuvant chemo-radiotherapy
                                 with vs. without epoetin alfa for patients with high-risk cervial cancer: Results of a prospective, randomized, open and controlled
                                 AGO- and NOGGO-intergroup study. Ann Oncol 15(Suppl 3). October 29, <span class="cit-pub-date">2004</span>. 29th European Society for Medical Oncology Congress, 29 October to 2 November 2004, Vienna, Austria. Abstract 447PD.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(80)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.10.708.80"
                             data-doi="10.1038/sj.bjc.6600801">
                           <div class="cit-metadata"><cite>Boogaerts M, Coiffier B, Kainz C, and the Epoetin Beta QOL Working Group. Impact of epoetin beta on quality of life in patients
                                 with malignant disease. <span class="cit-source">Br J Cancer</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">88</span>:<span class="cit-fpage">988</span>–95.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/sj.bjc.6600801&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12671693&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000182663700002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div><span id="related-urls"></span></div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/98/10/700.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/98/10/715.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/98/10.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="JNCI Journal of the National Cancer Institute" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">JNCI J Natl Cancer Inst</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">
                                    (17 May 2006) 
                                    </span>
                                 
                                 <span class="slug-vol">
                                    98
                                    </span><span class="slug-issue">
                                    (10):
                                    </span><span class="slug-pages">
                                    708-714.
                                    </span>
                                 <span class="slug-doi-wrapper">
                                    
                                    doi:
                                    
                                    <span title="10.1093/jnci/djj189" class="slug-doi">10.1093/jnci/djj189</span>
                                    </span>
                                 </cite>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/98/10/708.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="/content/98/10/708.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                        <li><a href="/content/98/10/708/suppl/DC1" rel="supplemental-data"
                              class="dslink-supplemental-table">Supplemental Table</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Classifications</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=BRIEF+COMMUNICATIONS&amp;sortspec=date&amp;submit=Submit">Brief Communication</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="usage-stats-link icon-link"><a href="/articleusage?gca=jnci;98/10/708" rel="nofollow">Article metrics</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jnci%3B98%2F10%2F708&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/98/10/708.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=98/10/708&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/98/10/708.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="/search?qbe=jnci%3B98%2F10%2F708&amp;citation=Bohlius%20et%20al.%2098%20%2810%29:%20708&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=jnci%3B98%2F10%2F708&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=16705125&amp;link_type=MED_NBRS"
                              class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jnci%3B98%2F10%2F708">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=jnci%3B98%2F10%2F708">Download citation</a></li>
                        <li><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jnci&amp;title=Recombinant%20Human%20Erythropoietins%20and%20Cancer%20Patients%3A%20Updated%20Meta-Analysis%20of%2057%20Studies%20Including%209353%20Patients%3A%20&amp;publicationDate=17%20May%202006&amp;author=Julia%20Bohlius%2C%20Jayne%20Wilson%2C%20Jerome%20Seidenfeld%2C%20Margaret%20Piper%2C%20Guido%20Schwarzer%2C%20Josie%20Sandercock%2C%20Sven%20Trelle%2C%20Olaf%20Weingart%2C%20Sue%20Bayliss%2C%20Benjamin%20Djulbegovic%2C%20Charles%20L.%20Bennett%2C%20Simon%20Langensiepen%2C%20Chris%20Hyde%2C%20Andreas%20Engert&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjnci%2Fdjj189&amp;volumeNum=98&amp;issueNum=10&amp;startPage=708&amp;endPage=714&amp;orderBeanReset=true"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/98/10/708.full?cited-by=yes&amp;legid=jnci;98/10/708#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/cgi/crossref-forward-links/98/10/708" rel="external-nw"
                              id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a href="/scopus-links/jnci/98/10/708?access_num=/jnci/98/10/708"
                              rel="external-nw"
                              id="cb-scopus-citing-articles">Citing articles via Scopus</a></li>
                        <li><a href="/external-ref?access_num=%2Fjnci%2F98%2F10%2F708&amp;link_type=ISI_CITING&amp;accnum_type=native"
                              rel="external-nw"
                              id="cb-isi-citing-articles">Citing articles via Web of Science</a></li>
                        <li><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/98/10/708.abstract&amp;link_type=GOOGLESCHOLAR">Citing articles via Google Scholar</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3ABohlius%20author%3AJ.%22"
                              class="cb-art-gs-auth author-link">Articles by  Bohlius, J.</a></li>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AEngert%20author%3AA.%22"
                              class="cb-art-gs-auth author-link">Articles by  Engert, A.</a></li>
                        <li class="cb-art-gs-rel similar-link"><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/98/10/708.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=16705125&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Bohlius%20J&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Bohlius, J.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Wilson%20J&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Wilson, J.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Seidenfeld%20J&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Seidenfeld, J.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Piper%20M&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Piper, M.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Schwarzer%20G&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Schwarzer, G.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Sandercock%20J&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Sandercock, J.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Trelle%20S&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Trelle, S.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Weingart%20O&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Weingart, O.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Bayliss%20S&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Bayliss, S.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Djulbegovic%20B&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Djulbegovic, B.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Bennett%20CL&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Bennett, C. L.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Langensiepen%20S&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Langensiepen, S.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Hyde%20C&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Hyde, C.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Engert%20A&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Engert, A.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="/content/98/10/708.full?related-urls=yes&amp;legid=jnci;98/10/708#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Share</span></h4>
                     <ol>
                        <li><a href="/email?gca=jnci%3B98%2F10%2F708&amp;current-view-path=/content/98/10/708.full">
                              Email this article</a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/10/708&amp;title=Recombinant%20Human%20Erythropoietins%20and%20Cancer%20Patients%3A%20Updated%20Meta-Analysis%20of%2057%20Studies%20Including%209353%20Patients+--+Bohlius%20et%20al.%2098%20%2810%29%3A%20708+--+&amp;doi=10.1093/jnci/djj189&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/10/708&amp;title=Recombinant%20Human%20Erythropoietins%20and%20Cancer%20Patients%3A%20Updated%20Meta-Analysis%20of%2057%20Studies%20Including%209353%20Patients+--+Bohlius%20et%20al.%2098%20%2810%29%3A%20708+--+&amp;doi=10.1093/jnci/djj189&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/short/98/10/708&amp;title=Recombinant%20Human%20Erythropoietins%20and%20Cancer%20Patients%3A%20Updated%20Meta-Analysis%20of%2057%20Studies%20Including%209353%20Patients+--+Bohlius%20et%20al.%2098%20%2810%29%3A%20708+--+&amp;doi=10.1093/jnci/djj189&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/10/708&amp;title=Recombinant%20Human%20Erythropoietins%20and%20Cancer%20Patients%3A%20Updated%20Meta-Analysis%20of%2057%20Studies%20Including%209353%20Patients+--+Bohlius%20et%20al.%2098%20%2810%29%3A%20708+--+&amp;doi=10.1093/jnci/djj189&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/10/708&amp;title=Recombinant%20Human%20Erythropoietins%20and%20Cancer%20Patients%3A%20Updated%20Meta-Analysis%20of%2057%20Studies%20Including%209353%20Patients+--+Bohlius%20et%20al.%2098%20%2810%29%3A%20708+--+&amp;doi=10.1093/jnci/djj189&amp;link_type=MENDELEY"><img src="/shared/img/common/social-bookmarking/mendeley.gif" alt="Add to Mendeley"
                                            title="Mendeley" /></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/10/708&amp;title=Recombinant%20Human%20Erythropoietins%20and%20Cancer%20Patients%3A%20Updated%20Meta-Analysis%20of%2057%20Studies%20Including%209353%20Patients+--+Bohlius%20et%20al.%2098%20%2810%29%3A%20708+--+&amp;doi=10.1093/jnci/djj189&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#fn-group-1">Footnotes</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
         </div>
         <div id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" type="text" name="fulltext" id="header-qs-input" />
                     <input type="hidden" name="submit" value="yes" />
                     
                     <input class="inline_button" type="image" alt="Go" src="/publisher/img/buttons/go.gif" />
                     
                     <div class="adv-search-link"><a href="/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="/content/current"><span>
                                 		  <span class="current-issue-date">
                                    October 2015
                                    </span><span class="toc-citation-volume">
                                    
                                    107
                                    </span><span class="toc-citation-issue">(10)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="/content/current"><img src="/content/107/10.cover.gif" alt="JNCI J Natl Cancer Inst" id="cover" /></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1"
                          src="/resource/htmlfiles/advert.html?p=Right1&amp;u=jnci.oxfordjournals.org/content/98/10/708.full"
                          width="0"
                          height="0"
                          frameborder="0"
                          scrolling="no"
                          class="resize_ad"></iframe>
                  
               </div>
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/about.html" rel=""
                              title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/contact_us.html" rel=""
                              title="Contact Us">Contact Us</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html"
                              rel=""
                              title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="HTTP://www.oxfordjournals.org/access_purchase/dispatch_dates.html#JNCI.JP"
                              rel=""
                              title="Dispatch date of next issue">Dispatch date of next issue</a>
                           
                        </li>
                        <li>
                           <a href="http://publicationethics.org/" rel=""
                              title="This journal is a member of the Committee on Publication Ethics (COPE)">This journal is a member of the Committee on Publication Ethics (COPE)</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" rel=""
                              title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                        <li>
                           <a href="http://medicine-and-health-careernetwork.oxfordjournals.org/jobseeker/search/results/?t730=&amp;t732=469986&amp;t731=&amp;t733=&amp;t735=&amp;t737=&amp;max=25&amp;site_id=20102"
                              rel=""
                              title="Journals Career Network">Journals Career Network</a>
                           
                        </li>
                     </ul>
                     
                     <p>
                        <a href="http://www.oxfordjournals.org/our_journals/jnci/episodes_2012.html">
                           <img alt="Podcast Logo" style="float:left"
                                src="http://www.oxfordjournals.org/podcasts/podcast_icon_35x35.gif" />JNCI Podcast</a>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Connect with us!</h3>
                     <a href="https://twitter.com/JNCI_Now">
                        <img class="small_margin" alt="Connect with us on Twitter!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/connect_twitter.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     <a href="https://www.facebook.com/thejnci">
                        <img class="small_margin" alt="Connect with us on Facebook!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/facebook.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     
                     <p>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <p>Carmen J. Allegra</p>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/editorial_board.html"
                              rel=""
                              title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor: 12.583</h3>
                     
                     <h3 class="five_year">5-Yr impact factor: 13.584</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>For the Media</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/press_room.html" rel=""
                              title="JNCI PRESS ROOM">JNCI PRESS ROOM</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/for_authors/index.html"
                              rel=""
                              title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html"
                              rel=""
                              title="Self Archiving/Public Access Policy">Self Archiving/Public Access Policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/ ">
                        <img alt="Open access options for authors - visit Oxford Open"
                             src="http://www.oxfordjournals.org/resource/image/promos/oxford_open_small.gif" />
                        </a>
                     <a href="http://www.oxfordjournals.org/oxfordopen/funder_policies/">
                        <img alt="RCUK Wellcome Trust Open Access"
                             src="http://www.oxfordjournals.org/resource/image/wellcome-trust-180x100.jpg" />
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="http://www.oxfordjournals.org/resource/image/pmc-logo.gif" />
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" rel=""
                              title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jnci.oxfordjournals.org/help/citetrack/index.dtl" rel=""
                              title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="/rss" rel="" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" rel=""
                              title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" rel=""
                              title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/classifiedadinprint.html"
                              rel=""
                              title="Classified Advertising">Classified Advertising</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300"];</script>
               </div>
            
            <div class="most-links-box js-marker">
               
               <div class="most-header">
                  
                  <h3>Most</h3>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/6/443?rss=1&amp;ssource=mfr">Breast Density and Cancer Risk: What Is the Relationship?</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/9/713?rss=1&amp;ssource=mfr">The Female Prostate</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/91/14/1194?rss=1&amp;ssource=mfr">Tobacco Smoke Carcinogens and Lung Cancer</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/107/6/djv048?rss=1&amp;ssource=mfr">Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,
                                 Poverty, and State</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/105/23/1799?rss=1&amp;ssource=mfr">Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study</a></li>
                        </ol>
                        	    <a href="http://jnci.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/3/205?rss=1&amp;ssource=mfc">New Guidelines to Evaluate the Response to Treatment in Solid Tumors</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/18/1371?rss=1&amp;ssource=mfc">Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/85/5/365?rss=1&amp;ssource=mfc">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International
                                 Clinical Trials in Oncology</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/13/1107?rss=1&amp;ssource=mfc">New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/1/4?rss=1&amp;ssource=mfc">What Is the Evidence That Tumors Are Angiogenesis Dependent?</a></li>
                        </ol>
                        	  <a href="http://jnci.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom"
                    src="/resource/htmlfiles/advert.html?p=Bottom&amp;u=jnci.oxfordjournals.org/content/98/10/708.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2105 - Print ISSN 0027-8874</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a> 
               <span>2015</span> Oxford University Press
               
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input type="image" src="/resource/image/buttons/go.gif" alt="Go"
                            class="inline_button" />
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript"
                 src="http://gab.cookie.oup.com/aws-cookie/oup.cookiepolicy.pack.js"
                 defer="defer"></script>
         
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jquery-ui.min.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jcarousellite.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/pf_oiunderbarinit.js"
                 type="text/javascript"></script>
         <script defer="defer" src="/resource/js/underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">
    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <noscript><img src="//ouptag.scholarlyiq.com/ntpagetag.gif?js=0" height="1" width="1"
                 border="0"
                 hspace="0"
                 vspace="0"
                 alt="" /></noscript><script type="text/javascript" src="//ouptag.scholarlyiq.com/ntpagetag.js"></script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   </body>
</html>